Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 12/20 | 0.44 |
| ▸ | INSR | P06213 | 5/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24959918 | 0.81 | MAP4K1 (0.73) | MAP4K1ALKINSREGFR | |
| SCHEMBL24959952 | 0.78 | EGFR (0.63) | MAP4K1EGFR | |
| SCHEMBL25947626 | 0.77 | MAP4K1 (0.63) | MAP4K1ALK | |
| SCHEMBL24960657 | 0.74 | REN (0.39) | — | |
| SCHEMBL18491223 | 0.73 | EGFR (0.73) | ALKINSREGFR | |
| SCHEMBL24959949 | 0.69 | MAP4K1 (0.69) | MAP4K1ALKINSREGFR | |
| SCHEMBL22822057 | 0.68 | EGFR (0.65) | EGFR | |
| SCHEMBL17059228 | 0.68 | LRRK2 (0.53) | ALKINSREGFRBRD4 | |
| SCHEMBL30378262 | 0.68 | ALK (0.77) | MAP4K1ALKINSREGFRMET | |
| SCHEMBL24327435 | 0.68 | ALK (0.77) | MAP4K1ALKINSREGFRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026840-A1 | COMPOUND USED AS EGFR KINASE INHIBITOR AND USE THEREOF | TYK MEDICINES, INC. (CN) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026840-A1 | COMPOUND USED AS EGFR KINASE INHIBITOR AND USE THEREOF | EGFR, ERBB2, ERBB4 | MAP4K1 34/4885ALK 68/4885INSR 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.